文献速递炎症性肠病

母亲暴露于生物制剂后婴儿的精神运动发育:DUMBO登记研究结果

Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-06-13

DUMBO是一项在西班牙60个中心进行的前瞻性观察性登记研究,纳入352名婴儿(343名母亲),评估孕期或哺乳期生物制剂暴露对婴儿第一年精神运动发育的影响。12个月时,暴露组ASQ-3总分正常比例(86% vs 74%;P=.031)和粗大运动域正常比例(91% vs 81%;P=.033)显著高于未暴露组,多因素分析显示早产(OR 0.3;95%CI 0.1-0.6)和母亲溃疡性结肠炎(OR 0.5;95%CI 0.3-0.9)与ASQ-3异常风险增加相关,而宫内生物制剂暴露对12个月ASQ-3评分无影响。结论认为孕期或哺乳期生物制剂暴露对婴儿精神运动发育无负面影响。

要点

  • 12个月时生物制剂暴露组ASQ-3总分正常比例86% vs 未暴露组74%(P=.031)。
  • 粗大运动域正常比例暴露组91% vs 未暴露组81%(P=.033)。
  • 早产(OR 0.3;95%CI 0.1-0.6)和母亲溃疡性结肠炎(OR 0.5;95%CI 0.3-0.9)与ASQ-3异常风险增加相关。

核心结论

  • 孕期或哺乳期因炎症性肠病暴露于生物制剂对婴儿精神运动发育无负面影响。

研究设计与样本

  • DUMBO是一项正在进行的、前瞻性、观察性登记研究,由GETECCU实施,纳入西班牙60个中心年龄≥18岁的炎症性肠病孕妇。
  • 共评估343名母亲所生的352名儿童,其中134名(38.1%)在孕期暴露于生物制剂,80名(22.7%)在哺乳期暴露,包括5名纯母乳喂养者。
  • 婴儿精神运动发育采用西班牙版年龄与发育进程问卷第三版(ASQ-3)在出生后第一年评估,任一领域ASQ-3评分低于正常下限视为异常。

主要发现

  • 12个月时,生物制剂暴露组ASQ-3总分正常比例显著高于未暴露组(86% vs 74%;P=.031)。
  • 12个月时,生物制剂暴露组粗大运动域正常比例显著高于未暴露组(91% vs 81%;P=.033)。
  • 多因素分析显示,早产(OR 0.3;95%CI 0.1-0.6)和母亲溃疡性结肠炎(OR 0.5;95%CI 0.3-0.9)与ASQ-3异常风险增加相关。
  • 其他变量包括宫内生物制剂暴露对12个月ASQ-3评分无影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The impact of biologic treatment for inflammatory bowel disease (IBD) during pregnancy and lactation on infant psychomotor development is barely studied. We investigated the effect of exposure to biologics in utero or during breastfeeding on the psychomotor development of offspring during their first year. METHODS: The study included patients and infants from DUMBO, an ongoing prospective, observational registry of GETECCU enrolling pregnant women (aged ≥18 years) with IBD from 60 centers across Spain. Mothers were followed up at each trimester during pregnancy and after delivery. Psychomotor development of infants was assessed using the Spanish version of the Ages and Stages Questionnaire 3rd edition (ASQ-3) during the first year of life. An ASQ-3 score below the normal limit in any domain was considered abnormal. RESULTS: In total, 352 children born to 343 women were assessed; 134 infants (38.1%) were exposed to biologics during pregnancy and 80 (22.7%) during lactation, including 5 who were exclusively breastfed. At 12 months, the proportions of infants with normal ASQ-3 total scores (86% vs 74%; P = .031) and normal gross motor domain scores (91% vs 81%; P = .033) were significantly higher in the biologics-exposed vs nonexposed subgroups. Multivariate analysis revealed that preterm birth (odds ratio, 0.3; 95% confidence interval, 0.1-0.6) and maternal ulcerative colitis (odds ratio, 0.5; 95% confidence interval, 0.3-0.9) were associated with an increased risk of abnormal ASQ-3. Other variables, including exposure to biologics in utero, had no impact on ASQ-3 scores at month 12. CONCLUSIONS: Exposure to biologics for IBD in utero or during breastfeeding has no negative impact on psychomotor development in infants. GOV, NUMBER: NCT03894228.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Palomino L, Velasco Rodríguez-Belvís M, Casanova MJ, et al. Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry. Clin Gastroenterol Hepatol. 2025. PMID: 40518059. doi:10.1016/j.cgh.2025.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。